Madrigal Pharmaceuticals

MDGL · Nasdaq · United States

Share price · MDGL

$398.08-126.29 (-24.08%) 3M

close as of 2026-11-18 · 24h delayed · vol 635K (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MDGL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-5.7%
  2. 9 Nov 2026+8.3%
  3. 3 Nov 2026-8.1%
  4. 26 Aug 2026+5.2%

    Nothing announced by MDGL that day or the session before.

  5. 30 Jul 2026-9.8%
  6. 3 Jun 2026+7.8%
  7. 26 Mar 2026+12.3%

    Nothing announced by MDGL that day or the session before.

  8. 19 Feb 2026-11.1%
  9. 9 Jan 2026-7.6%
  10. 6 Jan 2026-5.2%

    Nothing announced by MDGL that day or the session before.

Share of unusual movement by asset

For each asset, the share of MDGL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Resmetirom (Rezdiffra)
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—44%
Sessions with no dated event—52%

Assets

(4 total)
4Total Assets
1Approved
0Phase 3 / Filed
3Phase 1–2 / Early
1Diseases
Showing 4 of 4 assets
Target & Modality
Resmetirom(Rezdiffra)
Approved
Thyroid hormone receptor-betaSmall molecule
MASH / NASH
Phase 2
Diacylglycerol acyltransferase 2 (DGAT2)Small molecule
MASH / NASH
ARO-PNPLA3No recent activity
Phase 1
PNPLA3RNA / oligonucleotide
MASH / NASH
Preclinical / Unstaged
GLP-1 receptorSmall molecule
MASH / NASH

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Resmetirom · RezdiffraPhase 3NASH, Cirrhosis, Liver
Est. primary completion 2026-12 · NCT05500222 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Resmetirom · RezdiffraPhase 3Non-Alcoholic Fatty Liver Disease
Est. primary completion 2027-03 · NCT04951219 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Resmetirom · RezdiffraPhase 3NASH - Nonalcoholic Steatohepatitis
Est. primary completion 2028-01 · NCT03900429 · CT.gov ↗
What to watch
August 2028 (1)
Resmetirom · RezdiffraPhase 2MASH - Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2028-08 · NCT07335601 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Resmetirom · RezdiffraPhase 2MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2029-07 · NCT07763015 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$431M$72M$515M+ $446M short-term inv.—$121M operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$364M$91M$293M+ $546M short-term inv.$58M$23M operating cash flowreport ↗
2026-Q1$311M$109M$232M+ $586M short-term inv.$94M-$167M operating cash flowreport ↗
2025-Q3$287M$174M$301M+ $814M short-term inv.$114M$80M operating cash flowreport ↗
2025-Q2$213M$54M$191M+ $611M short-term inv.$42M-$47M operating cash flowreport ↗
2025-Q1$137M$44M$189M+ $659M short-term inv.$73M-$89M operating cash flowreport ↗
2024-Q3$62M$69M$238M+ $766M short-term inv.$107M-$67M operating cash flowreport ↗
2024-Q2$15M$71M$500M+ $563M short-term inv.$152M-$135M operating cash flowreport ↗
2024-Q1$0$71M$623M+ $437M short-term inv.$148M-$149M operating cash flowreport ↗
2023-Q4—$71M$100M+ $534M short-term inv.$112M-$80M operating cash flowreport ↗
2023-Q3$0$71M$62M+ $170M short-term inv.$99M-$85M operating cash flowreport ↗
2023-Q2$0$69M$77M+ $221M short-term inv.$86M-$75M operating cash flowreport ↗
2023-Q1—$62M$113M+ $216M short-term inv.$77M-$84M operating cash flowreport ↗
2022-Q4—$71M$332M+ $27M short-term inv.$86M-$59M operating cash flowreport ↗
2022-Q3—$68M$59M+ $94M short-term inv.$81M-$59M operating cash flowreport ↗
2022-Q2—$59M$53M+ $158M short-term inv.$71M-$57M operating cash flowreport ↗
2022-Q1—$48M$42M+ $178M short-term inv.$58M-$50M operating cash flowreport ↗
2021-Q4—$53M$36M+ $234M short-term inv.$65M-$48M operating cash flowreport ↗
2021-Q3—$55M$49M+ $250M short-term inv.$63M-$46M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$958M$389M$204M+ $785M short-term inv.$72M-$190M operating cash flowreport ↗

For fiscal 2025, Madrigal Pharmaceuticals reported revenue of $958.4M, up 432.1% YoY, and R&D spend of $388.53M, up 64.1% YoY. Cash and equivalents stood at $203.78M, with a net loss of $288.28M and a reported quarterly net burn of $288.28M.

During 2025, the company launched Rezdiffra in Germany following European Commission conditional marketing authorization and continued U.S. commercialization. Clinical developments included positive two-year data in compensated MASH cirrhosis from the MAESTRO-NAFLD-1 trial, with MAESTRO-NASH OUTCOMES data expected in 2027 and confirmatory MAESTRO-NASH outcomes data expected in 2028. The company also expanded its pipeline through global license agreements for MGL-2086, ervogastat, and six siRNA programs, and entered a senior secured financing agreement with up to $500.0M in commitments, including an initial term loan of $350.0M funded in July 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$180M$237M$105M+ $826M short-term inv.$116M-$456M operating cash flowreport ↗
2023-FY$0$272M$100M+ $534M short-term inv.$93M-$324M operating cash flowreport ↗
2022-FY$0$245M$332M+ $27M short-term inv.$74M-$225M operating cash flowreport ↗
2021-FY—$205M$36M+ $234M short-term inv.$60M-$184M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($35.0M), 178 sales ($69.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Kelley Shannon T · General CounselOpen-market sale1,077$400.00$431KForm 4
2026-11-06BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; directorOpen-market purchase60,400$383.01$23.1MForm 4
2026-11-06BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; directorOpen-market purchase13,740$388.29$5.3MForm 4
2026-11-06BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; directorOpen-market purchase2,000$396.61$793KForm 4
2026-11-04BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; directorOpen-market purchase5,586$366.99$2.1MForm 4
2026-11-04BAKER BROS. ADVISORS LP; Baker Bros. Advisors (GP) LLC; BAKER FELIX; BAKER JULIAN; 667, L.P.; Baker Brothers Life Sciences LP · director; director; director; director; director; directorOpen-market purchase10,080$368.11$3.7MForm 4
2026-09-11Sibold William John · director, President and CEOOpen-market sale60$533.09$32KForm 4
2026-09-11Sibold William John · director, President and CEOOpen-market sale106$534.06$57KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 375 reporting institutions held 23.8M shares ($12.1B, 102.3% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP2,141,701$1.1B
2JANUS HENDERSON GROUP PLC2,018,647$1.1B
3RTW INVESTMENTS, LP1,993,687$1.0B
4Avoro Capital Advisors LLC1,818,181$951.8M
5BlackRock, Inc.1,559,965$816.6M
6PAULSON & CO. INC.1,392,188$728.8M
7VANGUARD PORTFOLIO MANAGEMENT LLC841,145$440.3M
8VANGUARD CAPITAL MANAGEMENT LLC827,144$433.0M
9WELLINGTON MANAGEMENT GROUP LLP694,958$363.8M
10STATE STREET CORP609,525$319.1M
11FMR LLC511,728$267.9M
12GEODE CAPITAL MANAGEMENT, LLC455,870$238.7M
13CITADEL ADVISORS LLC453,843$237.6M
14WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC340,519$178.3M
15Invesco Ltd.329,519$172.5M